Effects of mouthrinses with linseed extract Salinum without/with chlorhexidine on oral conditions in patients with Sjögren's syndrome. A double-blind crossover investigation.
OBJECTIVE
To study the effect of mouthrinses with salivary replacement substances on oral conditions in patients with primary Sjögren's syndrome.


METHODS
Cross-over, double-blind study.


METHODS
Facilities at the Centre for Oral Health Sciences, Malmö University and at Malmö University Hospital, Malmö, Sweden.


METHODS
Twenty-two patients with Sjogren's syndrome.


METHODS
Linseed extract Salinum alone (Sal) or with addition of chlorhexidine (Sal/Chx) was used for mouthrinsing during 3-week periods of rinsings separated by a 3-week "wash-out" period.


METHODS
Recordings of percentages of sites with dental plaque and bleeding on probing, mirror friction test and microbiological analyses. Questionnaire on oral symptoms due to reduced salivation.


RESULTS
Dental plaque and bleeding on probing were reduced after Sal and after Sal/Chx. Friction was reduced after both treatments. No significant differences for counts of studied microbial groups were seen after Sal but the total anaerobically cultured microorganisms and of mutans streptococci fell after Sal/Chx (p<0.05 and p<0.001). Symptoms of oral dryness improved following Sal and Sal/Chx (p<0.05 and p<0.001 respectively). Speaking problems and burning mouth symptoms improved after use of Sal (p<0.05).


CONCLUSIONS
Positive effects on symptoms in patients with Sjögren's syndrome were seen after use of Salinum without or with chlorhexidine.
Johansson
G
G
Department of Periodontology, Centre for Oral Health Sciences, Malmö University, Sweden. Gunvor.Johansson@od.mah.se
Andersson
G
G
Edwardsson
S
S
Björn
A L
AL
Manthorpe
R
R
Attström
R
R
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use; D002054:Burning Mouth Syndrome / Q000150:complications / Q000188:drug therapy; D016009:Chi-Square Distribution; D002710:Chlorhexidine / Q000627:therapeutic use; D018592:Cross-Over Studies; D003773:Dental Plaque / Q000150:complications / Q000188:drug therapy; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D019597:Flax / Q000737:chemistry; D006801:Humans; D008297:Male; D008875:Middle Aged; D009055:Mouth / Q000382:microbiology; D009067:Mouthwashes / Q000627:therapeutic use; D017622:Periodontal Attachment Loss / Q000150:complications / Q000188:drug therapy; D008517:Phytotherapy; D010936:Plant Extracts / Q000627:therapeutic use*; D012463:Saliva / Q000378:metabolism; D012464:Saliva, Artificial / Q000627:therapeutic use*; D012859:Sjogren's Syndrome / Q000150:complications / Q000188:drug therapy*; D018709:Statistics, Nonparametric; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D000891:Anti-Infective Agents, Local; D004338:Drug Combinations; D009067:Mouthwashes; D010936:Plant Extracts; C450899:Salinum; D012464:Saliva, Artificial; D002710:Chlorhexidine